non-alcoholic steatohepatitis
Conditions
Interventions
Intervention group:Medical treatment+Viamin D: 600,000 IP for the first treatment,and additional 300,000 IU treatment in the following month for total 4 treatments.
Sponsors
Public Health and Clinical Center of Chengdu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Aged 18-60 years; (2) Satisfying the Guideline for Diagnosis and Treatment of NAFLD, China, 2018); ultrasonography shows fatty liver image, and may be confirmed bycomputerized tomography (CT) scanning or magnetic resonance imaging (MRI); (3) Liver function, including plasma ALT=2 folds of the normal or GGT=1.5 folds of the normal; (4) No habit of alcohol drinking (less than 140g/day for men, and 75g/day for wormen, and less than twice per week); (5) Serum calcium level and phosphate are normal; (6) Voluntarily participate in this study and sign informed consent
Exclusion criteria
Exclusion criteria: (1) Other serious diseases; (2) HIV infection; (3) Breast-feeding or pregnant women; (4) Unhealthy alcohol consumption; (5) Drug abuse or substitution therapy; (6) Use of vitamin D within the previous 6 months and during the study; (7) Weight loss >5% within 3 months before study entry; (8) alcoholic liver disease; (9) drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration, autoimmune liver disease; (10) Combine with other serious systemic diseases and mental illness; (11) poor compliance and voluntarily exit the study.ring medical treatment within 12 months before study entry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function biochemical index;B Ultrasound liver;glucose and lipids profiles;gut microbiota; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunology: T lymphocyte subsets; | — |
Countries
China
Contacts
Public ContactYilan Zeng
Public Health and Clinical Center of Chengdu
Outcome results
None listed